Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 25, 2011. The report details a share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 360,000 Ordinary shares of 25 pence each.
- Purchase Date: February 25, 2011.
- Price Range: Highest price paid was 1,182.5 pence per share; lowest price paid was 1,171.0 pence per share.
- Treasury Holdings (Settled): 483,704,284 shares (8.53% of total issued share capital).
- Treasury Holdings (Including Unsettled): 484,969,284 shares (9.35% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,187,160,919 shares.
Material Changes
The filing reports an increase in the Company's Treasury share holdings following the purchase of 360,000 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The shares purchased are intended to be held in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the latest quarterly or annual report to confirm the 8.53% ownership stake.
- Confirm the settlement status of the 1,265,000 shares included in the "including shares which have been purchased but not yet settled" figure.
- Review the Financial Services Authority's Disclosure and Transparency Rules to understand notification thresholds based on the 5,187,160,919 shares in issue.